Latest news with #PatrickTrucchio
Business Wire
10-07-2025
- Business
- Business Wire
Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat with Patrick Trucchio, Managing Director Equity Research at HC Wainwright at 8:00 am ET on July 14th, 2025. Management will participate in a fireside chat with Patrick Trucchio, analyst at HC Wainwright at 8:00 am ET on July 14th, 2025 Share A live audio webcast of the presentation will be accessible from the 'Events' page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). Compass is headquartered in London, UK, with offices in New York in the U.S. We envision a world where mental health means not just the absence of illness but the ability to thrive.
Business Wire
10-07-2025
- Business
- Business Wire
Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14 th, 8:00am ET
NEW YORK--(BUSINESS WIRE)--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat with Patrick Trucchio, Managing Director Equity Research at HC Wainwright at 8:00 am ET on July 14 th, 2025. Management will participate in a fireside chat with Patrick Trucchio, analyst at HC Wainwright at 8:00 am ET on July 14th, 2025 Share A live audio webcast of the presentation will be accessible from the 'Events' page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP360 synthetic psilocybin treatment, potentially a first in class treatment. COMP360 has Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and has received Innovative Licensing and Access Pathway (ILAP) designation in the UK for treatment-resistant depression (TRD). Compass is headquartered in London, UK, with offices in New York in the U.S. We envision a world where mental health means not just the absence of illness but the ability to thrive.
Yahoo
10-07-2025
- Business
- Yahoo
H.C. Wainwright Remains Bullish on Harmony Biosciences Holdings (HRMY)
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 30, H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) and set a price target of $70.00. A close-up of a pharmaceutical drug bottle, showcasing the potential of the company's innovative therapies. The company reported strong fiscal Q1 2025 results, with net revenue for WAKIX (pitolisant) in narcolepsy reaching $184.7 million for the quarter, reflecting a 20% year-over-year growth. It projects 2025 net revenue to be in the range of $820 to $860 million. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) also experienced a 19% year-over-year increase in net income, building on four consecutive years of profitability. It increased its cash and investments to more than $600 million on the balance sheet. Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage pharmaceutical company that develops and commercializes therapies to treat neurological disorders. Its product, WAKIX, is a molecule that increases histamine signaling in the brain by binding to H3 receptors. The company has one of the strongest pipelines for people with rare neurological diseases. While we acknowledge the potential of HRMY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
07-07-2025
- Business
- Yahoo
H.C. Wainwright Reiterates a Buy Rating on Beam Therapeutics (BEAM) With an $80 PT
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts. On July 1, H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Beam Therapeutics Inc. (NASDAQ:BEAM) and set a price target of $80.00. The analyst based the optimistic rating on the company's gene editing pipeline, especially with their base editing therapies. A patient undergoing MRI scanning to effectively diagnose Liver Diseases. Beam Therapeutics Inc. (NASDAQ: BEAM) is making considerable progress in several areas, including BEAM-101 for sickle cell disease, BEAM-302 for alpha-1 antitrypsin deficiency, and the ESCAPE platform for non-genotoxic conditioning. This progress has generated considerable investor interest in Beam Therapeutics Inc. (NASDAQ:BEAM), as it reflects the company's potential in both ex vivo and in vivo clinical programs, with commercialization readiness and a clear regulatory strategy. The analyst further reasoned that upcoming milestones are anticipated to drive additional value for Beam Therapeutics Inc. (NASDAQ:BEAM), including the initiation of a Phase 1 trial for BEAM-103 and the completion of patient dosing in the BEACON trial for BEAM-10. The company has established proof-of-concept and a fully integrated manufacturing platform, which, according to the analyst, fully equips it to deliver innovative genetic medications and supports the Buy rating. Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company that develops precision genetic medicines through base editing, a technology that allows efficient and predictable single-base changes at targeted genomic sequences. The company's lead programs focus on sickle cell disease and alpha-1 antitrypsin deficiency. Beam Therapeutics Inc. (NASDAQ:BEAM) is advancing programs in other genetic diseases as well, along with oncology and immunology. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302, BEAM-301, and BEAM-201. While we acknowledge the potential of BEAM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio
Yahoo
08-04-2025
- Business
- Yahoo
Alto Neuroscience initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price target Alto is redefining neuropsychiatric drug development through the application of precision medicine in psychiatry, a 'paradigm-shifting approach' that targets biomarker-defined patient populations, the analyst tells investors in a research note. The firm believes the company's 'differentiated' Precision Psychiatry Platform has the potential to optimize patient-treatment matching and outcomes in central nervous system disorders. Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on ANRO: Disclaimer & DisclosureReport an Issue Buy Rating Reaffirmed for Alto Neuroscience, Inc. Amid Promising Pipeline and Upcoming Data Readouts Promising Clinical Trials and Strong Financials Justify Buy Rating for Alto Neuroscience, Inc. Alto Neuroscience Advances Clinical Trials with Strong Financials Alto Neuroscience Announces Board Member Departures Alto Neuroscience, Inc. (ANRO) Q4 Earnings Cheat Sheet Sign in to access your portfolio
